Talk:SoRI-20041

Pharmacology Low‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Low	This article has been rated as Low-importance on the project's importance scale.

Chemicals Low‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Low	This article has been rated as Low-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about SoRI-20041.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

"antagonist-like", adjunct for releaser, given to inhibitor functionality simultaneously.[edit]

This compound appears as though it may introduce the same measure of DRI (cocaine) subjective intensity to that of a DRA (amphetamine), across the broad spectrum of release and duration as I speculate at this post offsite.

My premise is that what this RC does is allow for reuptake of dopamine to be inhibited at one and the same transporter, at the same time, that dopamine is released from by manner of binding when altered to allow a phosphorylated cascade out of that one and the same particular transporter. Which DRIs/DRAs previously did not, due to mutual exclusion of effect at the same individual transporter in any capacity. i.e. primacy for initial binding by either, etc. Nagelfar (talk) 06:43, 29 January 2012 (UTC)[reply]

Other MAT allosteric modulators:[edit]

Tropanyl that acts of allosteric modulator at SERT, may well fall within the spectrum of analogous compounds. Nagelfar (talk) 23:02, 8 December 2015 (UTC)[reply]